Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
27.81
+0.16 (0.58%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Anbio Biotechnology Revenue
In the year 2025, Anbio Biotechnology had annual revenue of $8.65M with 5.64% growth. Anbio Biotechnology had revenue of $4.06M in the half year ending December 31, 2025, with 11.22% growth.
Revenue (ttm)
$8.65M
Revenue Growth
+5.64%
P/S Ratio
141.16
Revenue / Employee
$320,253
Employees
27
Market Cap
1.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.65M | 461.70K | 5.64% |
| Dec 31, 2024 | 8.19M | 1.47M | 21.95% |
| Dec 31, 2023 | 6.71M | -16.83M | -71.49% |
| Dec 31, 2022 | 23.54M | 19.12M | 431.67% |
| Dec 31, 2021 | 4.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.68B |
| Embecta | 1.08B |
| Azenta | 595.03M |
| AtriCure | 534.53M |
| LeMaitre Vascular | 249.60M |
| STAAR Surgical Company | 239.44M |
| BioLife Solutions | 96.21M |
| Kestra Medical Technologies | 83.72M |
NNNN News
- 9 months ago - Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System - GlobeNewsWire
- 1 year ago - Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions - GlobeNewsWire
- 1 year ago - Anbio Biotechnology Announces Closing of Initial Public Offering - GlobeNewsWire
- 1 year ago - Anbio Biotechnology Announces Pricing of Initial Public Offering - GlobeNewsWire